Difference between revisions of "Spebrutinib (CC-292)"
Jump to navigation
Jump to search
m |
m |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Bruton's tyrosine kinase (BTK) inhibitor | Bruton's tyrosine kinase (BTK) inhibitor | ||
| − | [[Category: | + | ==Also known as== |
| − | [[Category: | + | *'''Code names:''' AVL-292, CC-292 |
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Oral medications]] | ||
| − | |||
[[Category:BTK inhibitors]] | [[Category:BTK inhibitors]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 23:32, 23 February 2021
Mechanism of action
Bruton's tyrosine kinase (BTK) inhibitor
Also known as
- Code names: AVL-292, CC-292